Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip(Vall d'Hebron Hospital Universitari), Nasser K. Altorki(Presbyterian Hospital), Caicun Zhou(Shanghai Pulmonary Hospital), Tibor Csőszi, Ihor Vynnychenko(Sumy State University), Oleksandr Goloborodko(National University Zaporizhzhia Polytechnic), Alexander Luft(Leningrad Regional Cancer Center), А. Л. Акопов(First Pavlov State Medical University of St. Petersburg), Alex Martínez‐Martí(Vall d'Hebron Institute of Oncology), Hirotsugu Kenmotsu(Shizuoka Cancer Center), Yuh‐Min Chen(National Yang Ming Chiao Tung University), Antonio Chella(Azienda Ospedaliera Universitaria Pisana), Shunichi Sugawara(Sendai Kousei Hospital), David Voong, Fan Wu(Roche (China)), Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee(Stanford Cancer Institute)
The Lancet
September 20, 2021
Cited by 1,465

Abstract


Related Papers

No related papers found

Powered by citation graph analysis